Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/29/12 | $12,500,000 | Series A-2 |
Morgenthaler New Leaf Venture Partners OrbiMed Advisors SR One | undisclosed |
| 04/22/14 | $5,000,000 | Series B |
Morgenthaler New Leaf Venture Partners OrbiMed Advisors Sofinnova Ventures SR One | undisclosed |
